UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000044518 |
|---|---|
| Receipt number | R000050861 |
| Scientific Title | A Study on Targeting the Rate of Change of Muscle-Adipose Tissue for the Prevention of Cardiovascular Disease |
| Date of disclosure of the study information | 2021/06/13 |
| Last modified on | 2021/06/13 00:03:30 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Study on Targeting the Rate of Change of Muscle-Adipose Tissue for the Prevention of Cardiovascular Disease
Acronym
A Study on Targeting the Rate of Change of Muscle-Adipose Tissue for the Prevention of Cardiovascular Disease
Scientific Title
A Study on Targeting the Rate of Change of Muscle-Adipose Tissue for the Prevention of Cardiovascular Disease
Scientific Title:Acronym
A Study on Targeting the Rate of Change of Muscle-Adipose Tissue for the Prevention of Cardiovascular Disease
Region
| Japan |
Condition
Condition
obesity
Sarcopenia
Classification by specialty
| Cardiology | Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
This study was conducted on patients with lifestyle-related diseases and no history of cardiovascular disease.
To examine the relationship between changes in skeletal muscle mass and body fat mass and factors associated with cardiovascular disease after 6 months of exercise, diet, and psychological intervention in patients.
Based on the results of the analysis, this study aims to set a target for the rate of change of skeletal muscle mass and body fat mass for the prevention of cardiovascular disease.
The primary endpoints of this study will be changes in skeletal muscle mass and body fat mass, and secondary endpoints will be body weight, blood pressure, glycolipid metabolic factors, adipokines, myokines, abdominal fat, arterial stiffness, physical fitness and physical activity, diet-related factors, and psychological indicators.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
The primary endpoints of this study will be changes in skeletal muscle mass and body fat mass.
Key secondary outcomes
Secondary endpoints will be body weight, blood pressure, glycolipid metabolic factors, adipokines, myokines, abdominal fat, arterial stiffness, physical fitness and physical activity, diet-related factors, and psychological indicators.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 120 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Selection Criteria
Patients who meet all of the following criteria are eligible
(1) Patients aged 20 years or older at the time of obtaining consent
(2) Outpatient/inpatient: Any
(3) Gender: No question
(4) Patients who are able to use the physical activity meter used in this study
(5) Patients who have received sufficient explanations for participation in this study and have given their free consent with full understanding.
Key exclusion criteria
Exclusion criteria
Patients who violate any of the following will not be included in this study
(1) Patients with severe hepatic or renal dysfunction
(2) Pregnant or lactating women
3) Patients with a history of wasting disease or condition causing extreme weight loss (severe infection, invasive surgery, malignancy, severe trauma, hyperthyroidism, etc.) within the past 6 months
(4) Patients after implantation of pacemakers and implantable defibrillators
5) Patients with psychiatric disorders that are difficult to manage
(6) Patients who are unable to obtain written consent or who do not understand the outline and purpose of the research
(7) Patients who are judged by the principal investigator to be inappropriate as research subjects.
Target sample size
1000
Research contact person
Name of lead principal investigator
| 1st name | yutaka |
| Middle name | |
| Last name | kimura |
Organization
Kansai Medical University
Division name
Health Science Center
Zip code
573-1010
Address
2-5-1 Shinmachi, Hirakata, Osaka
TEL
072-804-0101
kimuray@takii.kmu.ac.jp
Public contact
Name of contact person
| 1st name | Satoshi |
| Middle name | |
| Last name | Kurose |
Organization
Kansai Medical University
Division name
Health Science Center
Zip code
573-1010
Address
2-5-1 Shinmachi, Hirakata, Osaka
TEL
072-804-0101
Homepage URL
kurosesa@hirakata.kmu.ac.jp
Sponsor or person
Institute
Kansai Medical University
Health Science Center
Institute
Department
Personal name
Funding Source
Organization
Japan Society for the Promotion of Science
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kansai Medical University Center for Ethical Review
Address
2-5-1 Shinmachi, Hirakata, Osaka
Tel
072-804-2440
rinriirb@hirakata.kmu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
関西医科大学付属病院
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 06 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2019 | Year | 09 | Month | 10 | Day |
Date of IRB
| 2019 | Year | 10 | Month | 01 | Day |
Anticipated trial start date
| 2019 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2022 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Study type and design
Past and future starting cohort study
Research and survey items
The following items will be observed and examined, and the data will be used in this study. All of these items will be performed in routine medical care, and the frequency will be the same as in routine medical care. In the past-start cohort study, adipokines, myokines, and gene methylation rates will be assessed using blood specimens that are frozen and stored for secondary use in routine medical examinations and other studies.
1)Subject background: age, gender, diagnosis, medical history, height, weight, BMI, medication status, and lifestyle
2)Body composition: weight, BMI, skeletal muscle mass, body fat mass, limb skeletal muscle index, abdominal circumference
3)Blood tests: white blood cell, red blood cell, hemoglobin, lymphocyte count, total protein,albumin, AST, ALT
Creatinine, BUN, Na, K, Total cholesterol, HDL cholesterol, LDL cholesterol, TG, GLU, HbA1c, IRI, CRP, Adipokine, Myokine, TSH, FT4, FT3
4)Methylation rate of genes related to obesity
5)Urinalysis: protein, sugar, occult blood, urobilinogen
6)CT imaging: visceral fat area, subcutaneous fat area, body fat mass, lean mass, bone density
7)Arterial stiffness test: RHI, baPWV, ABI, systolic blood pressure, diastolic blood pressure, heart rate
8)Autonomic nervous system test: sympathetic nerve activity, parasympathetic nerve activity
9) Cardiac function test: electrocardiogram, echocardiography
10) Chest x-ray
11) Physical fitness assessment: grip strength, walking speed, isokinetic leg muscle strength, resting metabolism, anaerobic metabolic threshold, maximal oxygen uptake
12) Physical activity: number of steps, energy expenditure, life time assessment
Management information
Registered date
| 2021 | Year | 06 | Month | 13 | Day |
Last modified on
| 2021 | Year | 06 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050861
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
